Hypermethylated <i>PAX1</i> and <i>ZNF582</i> genes in the tissue sample are associated with aggressive progression of oral squamous cell carcinoma

Sun, Rui; Juan, Yi‐Chen; Su, Yee-Fun; Zhang, Wenbo; Yao, Yu; Yang, Hongyu; Yu, Guang‐Yan; Peng, Xin

doi:10.1111/jop.13035

Cited by 12 publications

(8 citation statements)

References 28 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the two genes are totally different in DNA sequences when using NCBI BLAST to compare. Several studies reported that ZNF582 expression was low in cancer, and low expression was associated with promoter hypermethylation and disease outcomes [ 29 , 30 , 31 , 32 , 33 , 34 ]. To assess if the two genes have any relationship in expression, we analyzed their correlation in breast cancer.…”

Section: Discussionmentioning

confidence: 99%

LncRNA ZNF582-AS1 Expression and Methylation in Breast Cancer and Its Biological and Clinical Implications

Wang

Katsaros²,

Biglia³

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Long non-coding RNAs (lncRNAs) play an important role in cellular activities and functions, but our understanding of their involvement in cancer is limited. Methods: TCGA data on RNA expression and DNA methylation were analyzed for lncRNAs’ association with breast cancer survival, using the Cox proportional hazard regression model. Fresh tumor samples and clinical information from 361 breast cancer patients in our study were used to confirm the TCGA finding on ZNF582-AS1. A RT-qPCR method was developed to measure ZNF582-AS1 expression. Survival associations with ZNF582-AS1 were verified with a meta-analysis. In silico predictions of molecular targets and cellular functions of ZNF582-AS1 were performed based on its molecular signatures and nucleotide sequences. Results: ZNF582-AS1 expression was lower in breast tumors than adjacent normal tissues. Low ZNF582-AS1 was associated with high-grade or ER-negative tumors. Patients with high ZNF582-AS1 had a lower risk of relapse and death. These survival associations were confirmed in a meta-analysis and remained significant after adjustment for tumor grade, disease stage, patient age, and hormone receptor status. Correlation analysis indicated the possible suppression of ZNF582-AS1 expression by promoter methylation. Bioinformatics interrogation of molecular signatures suggested that ZNF582-AS1 could suppress tumor cell proliferation via downregulating the HER2-mediated signaling pathway. Analysis of online data also suggested that HIF-1-related transcription factors could suppress ZNF582-AS1 expression, and the lncRNA might bind to hsa-miR-940, a known oncogenic miRNA in breast cancer. Conclusions: ZNF582-AS1 may play a role in suppressing breast cancer progression. Elucidating the lncRNA’s function and regulation may improve our understanding of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA ZNF582-AS1 Expression and Methylation in Breast Cancer and Its Biological and Clinical Implications

Wang

Katsaros²,

Biglia³

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…In the last decade, a growing body of evidence has implied an emerging tumor suppressing role of PAX1 in various human cancers, including cervical cancer ( Huang et al, 2010 ; Kan et al, 2014 ; Lai et al, 2014 ; Liu H. et al, 2020 ; Li et al, 2021 ), ovarian cancer ( Hassan et al, 2017 ), colorectal carcinoma ( Huang et al, 2017 ), parathyroid tumor ( Singh et al, 2022 ), as well as oral squamous cell carcinoma ( Huang et al, 2014 ; Cheng et al, 2018 ; Sun et al, 2020 ), and so on. Higher DNA methylation levels of PAX1 were observed in most kinds of cancer cells ( Lai et al, 2008 ; Huang et al, 2010 ; Cheng et al, 2016 ; Huang et al, 2016 ; Huang et al, 2017 ; Su et al, 2019 ; Tang et al, 2019 ; Zhao et al, 2020 ; Singh et al, 2022 ), significantly strengthened the observation that PAX1 often acts as a tumor suppressor.…”

Section: Mutations and Dysregulation Of Pax1 In Diseasesmentioning

confidence: 99%

An overview of PAX1: Expression, function and regulation in development and diseases

Kong²,

Jia³

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Transcription factors play multifaceted roles in embryonic development and diseases. PAX1, a paired-box transcription factor, has been elucidated to play key roles in multiple tissues during embryonic development by extensive studies. Recently, an emerging role of PAX1 in cancers was clarified. Herein, we summarize the expression and functions of PAX1 in skeletal system and thymus development, as well as cancer biology and outline its cellular and molecular modes of action and the association of PAX1 mutation or dysregulation with human diseases, thus providing insights for the molecular basis of congenital diseases and cancers.

show abstract

“…Positive correlations were also observed between DNA-methylation level and OSCC severity, including tumor size, stage, and bone invasiveness among primary OSCC patients, as well as bone invasion among recurrent OSCC patients. In addition, methylation levels were higher among recurrent OSCC than primary OSCC patients [ 74 ].…”

Section: Current Available Techniquesmentioning

confidence: 99%

Current Insights into Oral Cancer Diagnostics

Su¹,

Chen²,

Tsai

et al. 2021

Diagnostics

View full text Add to dashboard Cite

Oral cancer is one of the most common head and neck malignancies and has an overall 5-year survival rate that remains below 50%. Oral cancer is generally preceded by oral potentially malignant disorders (OPMDs) but determining the risk of OPMD progressing to cancer remains a difficult task. Several diagnostic technologies have been developed to facilitate the detection of OPMD and oral cancer, and some of these have been translated into regulatory-approved in vitro diagnostic systems or medical devices. Furthermore, the rapid development of novel biomarkers, electronic systems, and artificial intelligence may help to develop a new era where OPMD and oral cancer are detected at an early stage. To date, a visual oral examination remains the routine first-line method of identifying oral lesions; however, this method has certain limitations and as a result, patients are either diagnosed when their cancer reaches a severe stage or a high-risk patient with OPMD is misdiagnosed and left untreated. The purpose of this article is to review the currently available diagnostic methods for oral cancer as well as possible future applications of novel promising technologies to oral cancer diagnosis. This will potentially increase diagnostic options and improve our ability to effectively diagnose and treat oral cancerous-related lesions.

show abstract

Hypermethylated PAX1 and ZNF582 genes in the tissue sample are associated with aggressive progression of oral squamous cell carcinoma

Cited by 12 publications

References 28 publications

LncRNA ZNF582-AS1 Expression and Methylation in Breast Cancer and Its Biological and Clinical Implications

LncRNA ZNF582-AS1 Expression and Methylation in Breast Cancer and Its Biological and Clinical Implications

An overview of PAX1: Expression, function and regulation in development and diseases

Current Insights into Oral Cancer Diagnostics

Contact Info

Product

Resources

About